Answers are grounded in this paper and cite their sources.
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Pediatric Acute Lymphoblastic Leukemia (ALL) include evidence-based, consensus-driven recommendations from a multidisciplinary panel of experts in the United States with knowledge and experience in the management of patients with pediatric ALL within maximal resource settings, such as those present at NCCN Member Institutions. The International Adaptations of the NCCN Guidelines address the availability of resources, metabolic differences in populations, and regulatory status of health care technologies used in cancer care in a specific country or region. These targeted regional resources are created to combat increasing cancer rates and provide treatment recommendations that are more specific and unique to each region or country. These resources are updated biennially; for the most current version, please go to http://www.nccn.org/global/what-we-do/international-adaptations . This manuscript reviews the recommendations outlined in the International Adaptation of NCCN Guidelines for Sub-Saharan Africa (SSA; referred to as NCCN Guidelines for SSA within this discussion), Version 1.2025, published August 11, 2025, for the optimal diagnosis, workup, and treatment of pediatric ALL within the variable resource settings of SSA while highlighting the modifications required to optimize care when the maximal resource settings provided at comprehensive cancer centers such as NCCN Member Institutions are not available.
No takes yet. Share an insight, caveat, or question.
Inaba et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: